David Q. Pham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Q. Pham has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Antony Q. Pham
School of Pharmacy, University of California, San Francisco, California, USA
2 shared publicationsRoda Plakogiannis
Roda Plakogiannis PharmD, Assistant Professor of Pharmacy Practice, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University; Clinical Pharmacy Specialist in Ambulatory Care, Bellevue Hospital Center, New York, NY
2 shared publicationsHelen Kourlas
Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York
1 shared publicationHenry Cohen
Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York
1 shared publicationM. Mehta
Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University; Bronx‐Lebanon Hospital Center, Bronx, NY, USA
1 shared publicationValery Chu
Kingsbrook Jewish Medical Center, Brooklyn, New York
1 shared publication
Latest Publications
- 1 July 2007
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 47 (7) , 890-903
Inhaled Human [rDNA Origin] Insulin, a Novel Formulation for Diabetes Mellitus
Diabetic complications have been reduced significantly with the introduction of insulin more than 8 decades prior. Despite the proven benefits of normal glycemic levels, patients are deterred by the inconvenience and expect worse pain than there is on average with multiple daily insulin injections. Inhaled insulin was approved by the Food and Drug Administration in early 2006 and is a novel product that introduces inhaled insulin as an alternate to the traditional subcutaneous delivery system, and hence could potentially improve patient compliance. The objective of this article is to review the clinical pharmacology, pharmacokinetic and pharmacodynamic properties, clinical efficacy, and tolerability of inhaled insulin.
- 1 July 2007
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 47 (7) , 890-903
Inhaled Human [rDNA Origin] Insulin, a Novel Formulation for Diabetes Mellitus
Diabetic complications have been reduced significantly with the introduction of insulin more than 8 decades prior. Despite the proven benefits of normal glycemic levels, patients are deterred by the inconvenience and expect worse pain than there is on average with multiple daily insulin injections. Inhaled insulin was approved by the Food and Drug Administration in early 2006 and is a novel product that introduces inhaled insulin as an alternate to the traditional subcutaneous delivery system, and hence could potentially improve patient compliance. The objective of this article is to review the clinical pharmacology, pharmacokinetic and pharmacodynamic properties, clinical efficacy, and tolerability of inhaled insulin.
- 10 April 2007
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 61 (5) , 864-872
Ranolazine: a novel agent that improves dysfunctional sodium channels
Treatment for coronary heart disease is usually directed at either increasing myocardial oxygen supply or decreasing myocardial oxygen demand. Although combination therapy with beta-blockers, calcium-channel blockers and nitrates are effective, many patients suffer from adverse effects of hypotension and bradycardia. Ranolazine is a novel medication that reduces ischaemia by preventing sodium induced calcium overload in myocardial cells without adversely affecting haemodynamic parameters. This agent is the first in the USA to be approved to treat angina in over 10 years. The purpose of this review is to evaluate the pharmacology, pharmacokinetics, clinical trials for safety and efficacy, precautions, adverse effects, drug interactions, and dosage and administration of ranolazine in the treatment of chronic stable angina and acute coronary syndrome.
- 10 April 2007
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 61 (5) , 864-872
Ranolazine: a novel agent that improves dysfunctional sodium channels
Treatment for coronary heart disease is usually directed at either increasing myocardial oxygen supply or decreasing myocardial oxygen demand. Although combination therapy with beta-blockers, calcium-channel blockers and nitrates are effective, many patients suffer from adverse effects of hypotension and bradycardia. Ranolazine is a novel medication that reduces ischaemia by preventing sodium induced calcium overload in myocardial cells without adversely affecting haemodynamic parameters. This agent is the first in the USA to be approved to treat angina in over 10 years. The purpose of this review is to evaluate the pharmacology, pharmacokinetics, clinical trials for safety and efficacy, precautions, adverse effects, drug interactions, and dosage and administration of ranolazine in the treatment of chronic stable angina and acute coronary syndrome.
- 1 April 2007
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 27 (4) , 595-599
Cinnamon Supplementation in Patients with Type 2 Diabetes Mellitus
Diabetes mellitus is the sixth leading cause of death in the United States, and most patients with the disease have type 2 diabetes. The effectiveness of cinnamon supplementation in patients with type 2 diabetes has received a great deal of media attention after a study was published in 2003. Although the efficacy of cinnamon in patients with diabetes has not been established, many patients seek other therapies and supplement their prescribed pharmacologic therapy with cinnamon. We conducted a literature search, limited to English‐language human studies, using MEDLINE (1966–August 2006), EMBASE (1980–August 2006), International Pharmaceutical Abstracts (1970–August 2006), and Iowa Drug Information Service (1966–August 2006). References from articles and clinical trials were reviewed for additional sources; no abstracts were reviewed. We found two prospective, randomized, double‐blind, placebo‐controlled, peer‐reviewed clinical trials and one prospective, placebo‐controlled, peer‐reviewed clinical trial that evaluated the efficacy of cinnamon supplementation in patients with type 2 diabetes; a total of 164 patients were involved in these trials. Two of the studies reported modest improvements in lowering blood glucose levels with cinnamon supplementation in small patient samples. One trial showed no significant difference between cinnamon and placebo in lowering blood glucose levels. Overall, cinnamon was well tolerated. These data suggest that cinnamon has a possible modest effect in lowering plasma glucose levels in patients with poorly controlled type 2 diabetes. However, clinicians are strongly urged to refrain from recommending cinnamon supplementation in place of the proven standard of care, which includes lifestyle modifications, oral antidiabetic agents, and insulin therapy.
- 1 April 2007
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 27 (4) , 595-599
Cinnamon Supplementation in Patients with Type 2 Diabetes Mellitus
Diabetes mellitus is the sixth leading cause of death in the United States, and most patients with the disease have type 2 diabetes. The effectiveness of cinnamon supplementation in patients with type 2 diabetes has received a great deal of media attention after a study was published in 2003. Although the efficacy of cinnamon in patients with diabetes has not been established, many patients seek other therapies and supplement their prescribed pharmacologic therapy with cinnamon. We conducted a literature search, limited to English‐language human studies, using MEDLINE (1966–August 2006), EMBASE (1980–August 2006), International Pharmaceutical Abstracts (1970–August 2006), and Iowa Drug Information Service (1966–August 2006). References from articles and clinical trials were reviewed for additional sources; no abstracts were reviewed. We found two prospective, randomized, double‐blind, placebo‐controlled, peer‐reviewed clinical trials and one prospective, placebo‐controlled, peer‐reviewed clinical trial that evaluated the efficacy of cinnamon supplementation in patients with type 2 diabetes; a total of 164 patients were involved in these trials. Two of the studies reported modest improvements in lowering blood glucose levels with cinnamon supplementation in small patient samples. One trial showed no significant difference between cinnamon and placebo in lowering blood glucose levels. Overall, cinnamon was well tolerated. These data suggest that cinnamon has a possible modest effect in lowering plasma glucose levels in patients with poorly controlled type 2 diabetes. However, clinicians are strongly urged to refrain from recommending cinnamon supplementation in place of the proven standard of care, which includes lifestyle modifications, oral antidiabetic agents, and insulin therapy.
- 1 March 2007
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 64 (5) , 490-494
Interaction potential between cranberry juice and warfarin
Purpose. The interaction potential between warfarin and cranberry juice is discussed.
- 1 March 2007
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 64 (5) , 490-494
Interaction potential between cranberry juice and warfarin
Purpose. The interaction potential between warfarin and cranberry juice is discussed.
- 1 September 2006
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 40 (9) , 1541-1545
Evaluating the Impact of Clinical Interventions by PharmD Students on Internal Medicine Clerkships: The Results of a 3 Year Study
Background: As the practice of pharmacy evolves, requiring more clinically oriented healthcare providers, PharmD programs expand their training to more hospital sites to expose students to management of a variety of disease states. These hospital sites often require proof of the impact of PharmD students on patient care over an extended period. This is the first long-term (3 year) study reported. Objective: To evaluate the impact of clinical interventions by PharmD students on internal medicine clerkships over a 3 year period at a 627 bed county hospital with 165 general medical/surgical beds and 10 internal medicine teams. Methods: Between January 1, 2003, and December 31, 2005, all pharmacy interventions at Kings County Hospital Center in Brooklyn, NY, were recorded and analyzed for percentage of contribution, acceptance rate, type, frequency, and impact level. Results: PharmD students contributed to 28.8% of all pharmacy interventions made, with an acceptance rate for interventions of 92%. The most frequent types of interventions performed by PharmD students involved providing drug information (46.8%), recommending alternative agents (10.8%), and providing drug indications (10.6%). Overall, 49.5% of PharmD student interventions were categorized as having moderate to high level impact. Conclusions: This study demonstrates that the impact of PharmD students on clinical interventions is significant and improves overall patient care over a long-term period.
- 1 September 2006
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 40 (9) , 1541-1545
Evaluating the Impact of Clinical Interventions by PharmD Students on Internal Medicine Clerkships: The Results of a 3 Year Study
Background: As the practice of pharmacy evolves, requiring more clinically oriented healthcare providers, PharmD programs expand their training to more hospital sites to expose students to management of a variety of disease states. These hospital sites often require proof of the impact of PharmD students on patient care over an extended period. This is the first long-term (3 year) study reported. Objective: To evaluate the impact of clinical interventions by PharmD students on internal medicine clerkships over a 3 year period at a 627 bed county hospital with 165 general medical/surgical beds and 10 internal medicine teams. Methods: Between January 1, 2003, and December 31, 2005, all pharmacy interventions at Kings County Hospital Center in Brooklyn, NY, were recorded and analyzed for percentage of contribution, acceptance rate, type, frequency, and impact level. Results: PharmD students contributed to 28.8% of all pharmacy interventions made, with an acceptance rate for interventions of 92%. The most frequent types of interventions performed by PharmD students involved providing drug information (46.8%), recommending alternative agents (10.8%), and providing drug indications (10.6%). Overall, 49.5% of PharmD student interventions were categorized as having moderate to high level impact. Conclusions: This study demonstrates that the impact of PharmD students on clinical interventions is significant and improves overall patient care over a long-term period.
- 1 December 2005
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 39 (12) , 2065-2072
Vitamin E Supplementation in Alzheimer's Disease, Parkinson's Disease, Tardive Dyskinesia, and Cataract: Part 2
OBJECTIVE: To review clinical trials evaluating the safety and efficacy of vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract. DATA SOURCES: Using the MeSH terms alpha-tocopherol, tocopherols, vitamin E, Parkinson disease, tardive dyskinesia, Alzheimer disease, cataract, and clinical trials, a literature review was conducted to identify peer-reviewed articles in MEDLINE (1966–July 2005). STUDY SELECTION AND DATA EXTRACTION: Published materials including original research, review articles, and meta-analyses were reviewed. Only English-language articles and trials that included vitamin E alone or in combination with other vitamins or minerals were reviewed. Emphasis was placed on prospective, randomized, double-blind, placebo-controlled clinical trials. DATA SYNTHESIS: The clinical studies demonstrated contradicting results regarding the benefits of vitamin E in Parkinson's disease, tardive dyskinesia, and cataract. The study reviewed for Alzheimer's disease seemed to show benefit when vitamin E was used; however, the statistical methods employed are questionable. There is enough evidence from large, well-designed studies to discourage the use of vitamin E in Parkinson's disease, cataract, and Alzheimer's disease. We recommend that vitamin E be considered a treatment option in patients with tardive dyskinesia only if they are newly diagnosed. CONCLUSIONS: We encourage patients to supplement with vitamin E–rich foods. The use of a daily multivitamin, which usually contains 30 IU of alpha-tocopherol, may be beneficial; however, we discourage individual vitamin E supplements that usually contain 400 IU of alpha-tocopherol.
- 1 December 2005
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 39 (12) , 2065-2072
Vitamin E Supplementation in Alzheimer's Disease, Parkinson's Disease, Tardive Dyskinesia, and Cataract: Part 2
OBJECTIVE: To review clinical trials evaluating the safety and efficacy of vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract. DATA SOURCES: Using the MeSH terms alpha-tocopherol, tocopherols, vitamin E, Parkinson disease, tardive dyskinesia, Alzheimer disease, cataract, and clinical trials, a literature review was conducted to identify peer-reviewed articles in MEDLINE (1966–July 2005). STUDY SELECTION AND DATA EXTRACTION: Published materials including original research, review articles, and meta-analyses were reviewed. Only English-language articles and trials that included vitamin E alone or in combination with other vitamins or minerals were reviewed. Emphasis was placed on prospective, randomized, double-blind, placebo-controlled clinical trials. DATA SYNTHESIS: The clinical studies demonstrated contradicting results regarding the benefits of vitamin E in Parkinson's disease, tardive dyskinesia, and cataract. The study reviewed for Alzheimer's disease seemed to show benefit when vitamin E was used; however, the statistical methods employed are questionable. There is enough evidence from large, well-designed studies to discourage the use of vitamin E in Parkinson's disease, cataract, and Alzheimer's disease. We recommend that vitamin E be considered a treatment option in patients with tardive dyskinesia only if they are newly diagnosed. CONCLUSIONS: We encourage patients to supplement with vitamin E–rich foods. The use of a daily multivitamin, which usually contains 30 IU of alpha-tocopherol, may be beneficial; however, we discourage individual vitamin E supplements that usually contain 400 IU of alpha-tocopherol.
- 1 November 2005
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 39 (11) , 1870-1878
Vitamin E Supplementation in Cardiovascular Disease and Cancer Prevention: Part 1
OBJECTIVE: To review clinical trials evaluating the safety and efficacy of vitamin E supplementation in cardiovascular disease and cancer prevention. DATA SOURCES: Using the MeSH search terms alpha-tocopherol, tocopherols, vitamin E, cardiovascular diseases, cancer, malignancy, and clinical trials, a literature review was conducted to identify peer-reviewed articles in MEDLINE (1966–July 2005). STUDY SELECTION AND DATA EXTRACTION: Published materials including original research, and previous meta-analyses were included. Only English-language articles and trials on vitamin E alone or in combination with other vitamins or minerals were reviewed. Emphasis was placed on prospective, randomized, double-blind, placebo-controlled clinical trials. DATA SYNTHESIS: Eight clinical studies demonstrated contradicting results regarding the benefits of vitamin E in the prevention of cardiovascular disease and cancer. There is enough evidence from large, well-designed studies to discourage the use of vitamin E in the primary prevention of cardiovascular disease. Secondary prevention requires more adequate clinical trials with selected populations to examine protective effects of vitamin E in cardiovascular disease. The findings of the studies reviewed do not provide evidence that vitamin E may reduce the risk of cancer; thus, at the present time, we do not recommend daily vitamin E intake for cancer prevention is not recommended. CONCLUSIONS: Available data do not support the supplementation of vitamin E in cardiovascular disease and cancer prevention.
- 1 November 2005
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 39 (11) , 1870-1878
Vitamin E Supplementation in Cardiovascular Disease and Cancer Prevention: Part 1
OBJECTIVE: To review clinical trials evaluating the safety and efficacy of vitamin E supplementation in cardiovascular disease and cancer prevention. DATA SOURCES: Using the MeSH search terms alpha-tocopherol, tocopherols, vitamin E, cardiovascular diseases, cancer, malignancy, and clinical trials, a literature review was conducted to identify peer-reviewed articles in MEDLINE (1966–July 2005). STUDY SELECTION AND DATA EXTRACTION: Published materials including original research, and previous meta-analyses were included. Only English-language articles and trials on vitamin E alone or in combination with other vitamins or minerals were reviewed. Emphasis was placed on prospective, randomized, double-blind, placebo-controlled clinical trials. DATA SYNTHESIS: Eight clinical studies demonstrated contradicting results regarding the benefits of vitamin E in the prevention of cardiovascular disease and cancer. There is enough evidence from large, well-designed studies to discourage the use of vitamin E in the primary prevention of cardiovascular disease. Secondary prevention requires more adequate clinical trials with selected populations to examine protective effects of vitamin E in cardiovascular disease. The findings of the studies reviewed do not provide evidence that vitamin E may reduce the risk of cancer; thus, at the present time, we do not recommend daily vitamin E intake for cancer prevention is not recommended. CONCLUSIONS: Available data do not support the supplementation of vitamin E in cardiovascular disease and cancer prevention.